| Code | CSB-RA006920MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Sirexatamab, targeting Dickkopf-1 (DKK1), a secreted protein that functions as an antagonist of the canonical Wnt signaling pathway. DKK1 binds to LRP5/6 co-receptors, preventing Wnt ligand interaction and subsequently inhibiting β-catenin-mediated transcription. This protein plays a critical role in bone metabolism, embryonic development, and tissue homeostasis. Aberrant DKK1 expression has been implicated in multiple pathological conditions, including various cancers where it contributes to immune evasion and tumor progression, particularly in multiple myeloma, as well as bone disorders and fibrotic diseases.
Sirexatamab is a humanized IgG1 monoclonal antibody that has been investigated in clinical trials for multiple myeloma and other malignancies. By neutralizing DKK1, this reference antibody aims to restore Wnt signaling and enhance anti-tumor immunity. This biosimilar antibody serves as a valuable research tool for investigating DKK1-mediated mechanisms in oncology, immunology, bone biology, and developmental studies, enabling researchers to explore therapeutic strategies targeting the Wnt pathway.
There are currently no reviews for this product.